)
Visual
test
Lineage Cell Therapeutics
Lineage Cell Therapeutics (LCTX) investor relations material
Lineage Cell Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Advanced OpRegen program with eight new clinical sites and durable 36-month efficacy, supported by Roche/Genentech and RMAT designation.
Strategic partnership with William Demant Invest secured up to $12 million for Resonance (ANP1) hearing loss program, validating the platform and funding preclinical milestones.
Initiated large-scale manufacturing for iLET Cell (Type 1 Diabetes), with early work suggesting scalable islet cell production and a go/no-go decision expected next quarter.
OPC-1 program dosed first patient in DOSED study for spinal cord injury, with no significant safety events and CIRM grant finalist status for up to $7 million in non-dilutive funding.
Business model leverages internal development and strategic partnerships, focusing on scalable pluripotent cell platform and value creation.
Financial highlights
Q3 2025 revenues were $3.7 million, down $0.1 million year-over-year; nine-month revenue was $7.9 million, up 20% year-over-year.
Operating expenses for Q3 2025 were $7.5 million, with R&D at $3.3 million and G&A at $4.2 million.
Net loss for Q3 2025 was $29.8 million ($0.13/share), mainly due to a $26.6 million non-cash warrant liability remeasurement; nine-month net loss was $64.4 million.
Cash, cash equivalents, and marketable securities totaled $40.5 million as of September 30, 2025, expected to fund operations into Q2 2027.
Recorded a $14.8 million non-cash impairment charge for abandonment of the VAC platform.
Outlook and guidance
Cash runway extends into Q2 2027, not including potential milestone payments from Roche/Genentech or CIRM grant funds.
Expects continued momentum in 2026, driven by OpRegen progress, expanded partnerships, and manufacturing innovations.
Up to $36 million in potential proceeds from warrant exercises and $38.7 million available under the ATM program.
Awaiting CIRM grant decision, which could offset up to 50% of OPC-1 trial costs and free up capital for other programs.
Ongoing pursuit of additional capital through equity, grants, and collaborations.
What triggers the $37M OpRegen warrant capital?
How to overcome T1D islet cell production scale?
Impact if CIRM grant for OPC1 is not received?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebJ
Strong growth, digital innovation, and margin expansion drive robust multi-year financial outlook. - 6 Feb004020
Operating profit rose on cost savings and high-value sales, with major US expansion underway. - 6 FebJOUT
Net sales up 31%, gross margin at 36.6%, and net loss narrowed to $3.3 million. - 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
Next Lineage Cell Therapeutics earnings date
Q4 202513 Mar, 2026
Lineage Cell Therapeutics
Next Lineage Cell Therapeutics earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Lineage Cell Therapeutics Inc is a biotechnology company developing cell-based therapies for degenerative diseases. The company focuses on regenerative medicine approaches for ophthalmology, neurology, and oncology, using proprietary cell manufacturing platforms. The company is headquartered in Carlsbad, California, and its shares are listed on the NYSE American.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage